

# Seeking physicians who care for patients with low-risk cancers for a research study of a single telephone interview

## Background:

Due to more screening, many more people are diagnosed with abnormal cells with a very low risk of ever turning into cancer. Many patients undergoing treatment for these abnormal cells believe they have cancer, which causes anxiety and reduces quality of life. Little prior research has explored how to improve communication about abnormal cells so that patients better understand their diagnosis.

## Study purpose:

Identify ideal ways to name and discuss low-risk abnormal cells by asking patients and doctors about the names they prefer for abnormal cells of the **breast, cervix, bladder or prostate**, and the reason for those preferences.

## You can participate if you:

- Practice anywhere in Canada
- Are a general surgeon, surgical oncologist, medical or radiation oncologist, family physician, nurse practitioner, or other type of clinician that sees patients with abnormal cells, sometimes referred to as Stage 0 or pre-cancer, of any of the following types:
  - Stage 0 ductal carcinoma in situ (DCIS) Group 1 or 2; detected by mammogram or biopsy; treated with surgery, and sometimes radiation therapy or hormone therapy
  - Cervical dysplasia; detected by Pap test or biopsy, either LSIL managed by repeat testing, or HSIL managed by excision or ablation
  - Stage 0 bladder cancer; detected by urine test, CT/MRI scan or cystoscopy; treated with resection and sometimes adjuvant therapy
  - Grade Group 1 prostate cancer; detected by rectal exam, ultrasound or biopsy; managed by repeat testing to detect progression, or treated with excision, and sometimes radiation therapy

## What you will be asked to do:

- Read and sign an online consent form
- Participate in a single telephone interview of about 20 minutes
- We will ask for your opinion about labels and language for abnormal cells of the breast, cervix, bladder or prostate

## To express interest or ask questions:

The research study is being conducted by Dr. Anna Gagliardi from the University Health Network (UHN) in Toronto with funding from the Canadian Cancer Society. If you are interested in participating or wish to learn more about the study, please contact the study coordinator at 416-340-4800 x6642 or [Mavis.Lyons@uhn.ca](mailto:Mavis.Lyons@uhn.ca). *Please note that information sent by email may be accessible by external parties and therefore not entirely secure. Please do not communicate personal sensitive information via e-mail.*